Product Images Ramipril
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 4 images provide visual information about the product associated with Ramipril NDC 51655-975 by Northwind Pharmaceuticals, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
51655-975-52 - 51655 975 52 Rev A 02 23
This is a description of Ramipril, a medication presented in the form of capsules. Each capsule contains 2.5mg of Ramipril. It's recommended to keep the medication in its original container and in a controlled temperature environment not exceeding 25°C. The medication should be stored out of the reach of children. The description includes the NDC number, LCN, and other relevant details of the product. This medication is available only with a doctor's prescription.*
Figure 1. Kaplan-Meier Estimates of the Composite Outcome of Myocardial Infarction, Stroke, or Death from Cardiovascular Causes in the Ramipril Group and the Placebo Group - ramipril fig1
This appears to be a graph or chart of some sort displaying the proportion of patients on Ramipril over a certain period of time. The values range from 0.0 to 0.2 and there is a noticeable drop at the end with a p-value of 0.0001. The X-axis appears to measure the days of follow-up, ranging from 500 to 1500. However, without any additional context, it is difficult to determine the precise meaning or purpose of this graph.*
Figure 2. The Beneficial Effect of Treatment with Ramipril on the Composite Outcome of Myocardial Infarction, Stroke, or Death from Cardiovascular Causes Overall and in Various Subgroups - ramipril fig2
This appears to be a table containing information related to a medical study. It references cardiovascular disease, diabetes, age, sex, hypertension, coronary artery disease, prior myocardial infraction, cerebrovascular disease, peripheral vascular disease, and microalbuminuria. The table includes a number of patients and an incidence of a composite outcome in the placebo group, as well as the relative risk in the Ramipril group with a confidence interval. Without additional context, it is difficult to provide further details on the study or its findings.*
Chemical Structure - ramipril str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.